

Contents

■	A clinical overview of dry eye	14
1.1.	The dry eye	15
1.2.	The wet eye	18
1.3.	The inflamed eye	19
1.4.	References.....	21
■	Investigation of dry eye	24
2.1.	Introduction	24
2.2.	History	24
2.3.	Findings	24
2.3.1.	Lid parallel conjunctival folds (LIPCOF)	24
2.3.2.	Meibomian gland dysfunction	26
2.4.	Diagnostic tests.....	27
2.4.1.	Notes on diagnostic tests	27
2.4.2.	Measurement of tear volume	27
2.4.2.1.	Schirmer's test	27
2.4.2.2.	Other tests of volume.....	30
2.4.3.	Measurement of tear film stability	30
2.4.4.	Integrity of the ocular surface.....	32
2.4.4.1.	Fluorescein test	32
2.4.4.2.	Rose Bengal test.....	33
2.4.5.	Measurement of the osmolality of tear fluid	34
2.5.	References.....	35
■	Eye-associated lymphoid tissue (EALT) and its relationship to sicca syndrome	38
3.1.	Overview of the dry eye	38
3.1.1.	Definition and forms	38
3.1.2.	Symptoms and investigations	38
3.1.3.	Epidemiology	38
3.1.4.	Effect of the mucosal immune system on dry eye.....	38
3.2.	Anatomy of the ocular surface and mucosal immune system	39
3.2.1.	Structure of the ocular surface and tear film	39
3.2.2.	Mucosal immune system of the ocular surface.....	40
3.2.2.1.	Components of the mucosal immune system.....	41
3.2.2.2.	The mucosal immune system of the ocular surface forms coherent eye-associated lymphoid tissue	43
3.3.	Influence of the mucosal immune system on dry eye.....	44
3.3.1.	The normal function of EALT is protective	44
3.3.2.	Deregulation of the mucosal immune system through chronic surface irritation in dry eye can lead to the loss of immune tolerance	44
3.3.3.	The loss of immune tolerance leads to chronic progressive immune-modulated inflammation with destruction of the ocular surface	46
3.4.	References.....	48

	The importance of autoimmune processes in sicca syndrome and glaucoma	56
4.1.	Introduction	56
4.2.	Tear fluid and sicca syndrome	58
4.3.	Natural autoimmunity	60
4.4.	References.....	61
	Preservatives and their relevance for the ocular surface	66
5.1.	Background	66
5.2.	Is the use of preservatives necessary?	66
5.3.	Preservatives	67
5.3.1.	Quaternary ammonium compounds	67
5.3.2.	Thiomersal.....	67
5.3.3.	Alcohols	69
5.3.4.	Sorbic acid	69
5.3.5.	EDTA	69
5.3.6.	Polidronium chloride	69
5.3.7.	Oxychloro complex.....	69
5.4.	Problems	69
5.5.	Special storage forms	69
5.6.	Single-dose drop containers	70
5.7.	Allergy	70
5.8.	When should preservative-free artificial tears be used?	70
5.9.	References.....	71
	Results of the German Register for Glaucoma Patients with Dry Eye	74
6.1.	Introduction	74
6.2.	Prevalence of concomitant diseases	74
6.3.	Gender and age differences	74
6.4.	Effect of anti-glaucoma agents and duration of glaucoma disease on the prevalence of dry eye	74
6.5.	Benzalkonium chloride/anti-glaucoma active substances as cofactors for dry eye in glaucoma patients	75
6.6.	Ways to improve compliance in glaucoma patients	75
6.7.	References.....	76
	PEX glaucoma as a model of glaucoma with sicca symptoms	80
7.1.	Background	80
7.2.	Involvement of the conjunctiva in the PEX process.....	80
7.3.	Tear function in PEX syndrome/glaucoma	81
7.4.	Composition of tear fluid in PEX syndrome/glaucoma.....	82
7.5.	Dry eye in PEX syndrome/glaucoma	84
7.6.	References.....	84

	Importance and availability of preservative-free eye drops	88
8.1.	Tolerability	88
8.2.	Adherence and persistence	89
8.3.	Success of glaucoma filtering surgery.....	89
8.4.	Alternatives to benzalkonium chloride.....	90
8.5.	References.....	90
	Compliance in glaucoma patients	94
9.1.	Introduction	94
9.2.	The different types of non-compliance	94
9.3.	Current studies	95
9.4.	Reasons for non-compliance	96
9.5.	Possibilities for improving compliance.....	96
9.6.	References.....	97
	Index	100